Zdrowie i gospodarka · 18/09/2023
FDA Releases Draft Guidance on Labeling for Biosimilar and Interchangeable Biosimilar Products
The FDA has released a draft guidance to help industry applicants develop labeling for proposed biosimilar and interchangeable biosimilar products, which is expected to revise and replace existing guidance when finalized.
Source: Federal Register — Food and Drug AdministrationOpen original release →